Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783120 | 0.82 | KMT2A (0.47) | MEN1KMT2ALMNANPSR1 | |
| SCHEMBL9913696 | 0.76 | MEN1 (0.76) | POLBMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1034033 | 0.75 | LMNA (0.74) | GAAPOLBMEN1KMT2ALMNA | |
| SCHEMBL8611070 | 0.74 | MEN1 (0.79) | GAAPOLBMEN1KMT2ALMNA | |
| SCHEMBL2784422 | 0.72 | GAA (0.41) | GAAMEN1KMT2ALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11741238 | 0.72 | LMNA (0.70) | GAAPOLBMEN1KMT2ALMNA | |
| SCHEMBL11145527 | 0.71 | LMNA (0.65) | GAAPOLBMEN1KMT2ALMNA | |
| SCHEMBL13784260 | 0.71 | MEN1 (0.68) | POLBMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL23175171 | 0.69 | NUDT1 (0.44) | SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL5554503 | 0.68 | NUDT1 (0.38) | LMNASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198387-B2 | Proton-conducting compound and proton-conducting polymer | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | NIPPON STREEL CHEMICAL CO., LTD (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2078715-A1 | PROTON CONDUCTING COMPOUND AND PROTON CONDUCTING POLYMER | Nippon Steel Chemical Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | HRH3, H1-3, H1-4 | GAA 4346/4885POLB 3404/4885MEN1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.